新型雌激素受体 - 针对激素受体阳性乳腺癌的向疗法
Nina E Neill1, Lauren A Mauro2, Angela Pennisi2
1Inova Schar Cancer Institute, Fairfax, Virginia, USA. ninaeneill@gmail.com.
Current treatment options in oncology
|March 31, 2025
概括
激素受体阳性,HER2阴性转移性乳腺癌 (HR+/HER2-MBC) 的治疗依赖于内分泌疗法. CDK4/6抑制剂是第一线的,但耐药性需要针对性疗法进行分子分析,例如口服SERD或AKT途径抑制剂.
科学领域:
- 在瘤学瘤学.
- 乳腺癌的医疗治疗方法
- 癌症治疗中的分子生物学.
背景情况:
- 内分泌疗法是HR+/HER2- MBC的标准治疗方法.
- CDK4/6抑制剂改善了无进展生存率 (PFS) 和整体生存率 (OS),并被推作为一线治疗.
- 对CDK4/6抑制剂的耐药性是一个重大的临床挑战,通常会导致标准内分泌单独治疗的不良结果.
研究的目的:
- 审查HR+/HER2-MBC目前的治疗环境,重点关注基于内分泌的疗法和耐药性机制.
- 突出分子分析的重要性,以指导CDK4/6抑制剂失效后的后续治疗决策.
- 讨论新兴疗法和未来管理患者群体的方向.
主要方法:
- 审查当前的临床证据和关于内分泌治疗和针对HR+/HER2-MBC的向药物的新兴数据.
- 基于分子变化 (例如ESR1,PIK3CA突变) 的治疗结果分析.
- 讨论考虑患者因素和疾病特征的治疗顺序策略.
主要成果:
- 用CDK4/6抑制剂进行一线治疗与延长PFS和OS有关.
- 在CDK4/6抑制剂耐药之后,内分泌单独治疗显示出有限的疗效 (例如,EMERALD试验对照组中PFS的中位数为1.9个月).
- 在进展时的分子分析确定了可操作的目标:ESR1突变的口服SERD,PIK3CA/AKT1突变的capivasertib或PTEN无活化.
结论:
- 在HR+/HER2- MBC中选择最佳的CDK4/6后抑制剂疗法时,分子分析至关重要.
- 向疗法,包括口服SERD和AKT途径抑制剂,提供基于特定突变的个性化治疗选择.
- 未来对新药的批准,特别是SERDs,将进一步扩大HR+/HER2-MBC的治疗策略.
相关概念视频
Targeted Cancer Therapies
7.4K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.4K
Internal Receptors
68.9K
Many cellular signals are hydrophilic and therefore cannot pass through the plasma membrane. However, small or hydrophobic signaling molecules can cross the hydrophobic core of the plasma membrane and bind to internal, or intracellular, receptors that reside within the cell. Many mammalian steroid hormones use this mechanism of cell signaling, as does nitric oxide (NO) gas.
68.9K
Transducer Mechanism: Nuclear Receptors
1.2K
Nuclear receptors, or NRs, are unique transcription factors that regulate gene transcription and affect the cellular pathways involved in reproduction, development, or metabolism. Their ability to be stimulated by small lipophilic ligands and control vital cellular processes makes them ideal drug targets. Nearly 10-15% of currently prescribed drugs target these receptors.
About 48 different soluble family members of nuclear receptors are identified that can be divided into two main classes:
About 48 different soluble family members of nuclear receptors are identified that can be divided into two main classes:
1.2K
Mitogens and the Cell Cycle
6.3K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.3K
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
103
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
103
Transducer Mechanism: Enzyme-Linked Receptors
2.3K
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Major types that are helpful drug targets include:
2.3K


